ZIM
PETX

Zacks Investment Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Zacks Investment Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-11,108
Closed -$206K – 798
2014
Q1 		$206K Buy
+11,108
New +$223K 0.01% 641

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Zacks Investment Management's PETX Position: Q2 2014 in Review

Zacks Investment Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2014, closing a stake of 11,108 shares — an estimated $206K sold.

Zacks Investment Management first reported a position in PETX in Q1 2014 and held it in 1 quarter. The position peaked at $206K in Q1 2014. 89 funds tracked by Wall St. Rank hold PETX as of Q2 2014.

  • Zacks Investment Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Zacks Investment Management sold 11,108 Aratana Therapeutics, Inc. shares in Q2 2014, an estimated $206K.
  • Zacks Investment Management first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Zacks Investment Management's Aratana Therapeutics, Inc. position peaked at $206K in Q1 2014.
  • 89 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2014.

Based on Zacks Investment Management's 13F filing for Q2 2014, filed 12 Aug 2014.